CRISPR-Cas9 In Vivo Gene Editing for Transthyretin AmyloidosisJulian D. Gillmore, David Lebwohl, Kathryn Walsh et al.|New England Journal of Medicine|2021Cited by 1.7k
CRISPR-Cas9 In Vivo Gene Editing of <i>KLKB1</i> for Hereditary AngioedemaHilary Longhurst, Danny M. Cohn, Karen Lindsay et al.|New England Journal of Medicine|2024Cited by 177
CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosisJulian D. Gillmore, David Lebwohl, Ed Gane et al.|Yearbook of pediatric endocrinology|2022Cited by 47
NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in <i>In Vivo</i> Models of AML and ALLEliana Ruggiero, Birgit C. Schultes, Dai Liu et al.|Blood|2020Cited by 1